AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comNOV 33 min read$RVTY

Revvity Inc (RVTY) (Q3 2026) Earnings Call Highlights: Strong Organic Growth

Revvity Inc (RVTY) reported Q3 2026 earnings, highlighting 7% organic growth but guiding Q4 growth down to 5% due to lower reagent and software growth. APAC saw a low single-digit decline, and China's immunodiagnostics business remains a margin headwind. Software growth is expected to moderate, and AI demand is emerging but not yet quantified. The company confirmed sustainable incremental margins in the low 40s and expects a durable pharma biotech recovery.

Original reporting
finance.yahoo.com
Published Nov 3, 2026, 11:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Revvity Inc (RVTY) (Q3 2026) Earnings Call Highlights: Strong Organic Growth — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$RVTYBearishMed
01

Why it matters

The guidance downgrade is likely to weigh on the stock, while the company’s lack of share buybacks removes a potential catalyst for EPS uplift.

02

Market read

Guidance slowdown may trigger a sell‑off in RVTY and could influence sentiment toward similar diagnostics firms.

03

What to watch

Potential upside from high-content screening acceleration and upcoming instrument backlog growth.

Relevance 8/10Novelty 8/10Timing: post-earnings Q3 2026 call

Background

Revvity's Q3 2026 earnings call highlighted strong organic growth but warned of a step‑down in Q4 due to lower reagent and software growth, FX headwinds, and a pending China divestiture.

Company-level read

Ticker impact

$RVTYBearishHigh confidence
Context

Q4 organic growth guidance steps down to ~5% from 7% in Q3, with lower reagent and software growth, indicating a slowdown.

Expected impact

likely downward pressure as investors price in slower growth and lack of buybacks

Evidence & confidence

The earnings call disclosed fresh guidance that is materially lower than prior expectations, a primary catalyst for price movement.

Market effects

Sector

Life sciences sector may see broader scrutiny on growth forecasts as Revvity signals slower organic growth.

Regional

APAC region, especially China, could face pressure on related diagnostics and reagent suppliers.

Global

Modest; impacts investors tracking biotech and diagnostics equities.

Counterpoint

What could challenge this read

If AI demand accelerates faster than expected, the guidance may be overly conservative, offering upside.

Key entities

  • company
    Revvity Inc

    US‑listed life sciences diagnostics and reagents provider (ticker RVTY).

  • executive
    Maxwell Krakowiak

    Chief Financial Officer who provided the guidance details.

  • executive
    Prahlad Singh

    Chief Executive Officer who discussed AI demand and instrument backlog.

Read at source← All news

StoryRevity reports Q3 2026 earnings beat and lifts full‑year revenue and EPS outlook

Also covered by

4 outlets

Related articles

NOV 4
$RVTYHighAI 8/10

Revvity Q3 Earnings Call Highlights

Revvity reported Q3 earnings, highlighting AI-driven demand growth in high-content screening instruments, with revenue up 4% and backlog expansion across categories. Diagnostics revenue reached $330M, with mid-single-digit growth. The company raised its 2026 organic growth outlook to 5% and expects Q4 revenue of ~$755M. Margins improved, and free cash flow was strong. Revvity plans to discuss its AI strategy and outlook at an Investor Day event.

finance.yahoo.com2 min
NOV 3
$RVTYHigh

Revvity (RVTY) Q3 2026 Earnings Call Transcript

Revvity (RVTY) reported Q3 2026 earnings, highlighting AI-driven demand growth across its portfolio, including high-content screening, life sciences reagents, and detection instruments. The company expects 5% full-year organic growth and adjusted EPS of $5.40-$5.45, up from initial forecasts. Revvity also launched new AI-native offerings in its signals software business and a new diagnostic kit for early type 1 diabetes detection in Europe.

finance.yahoo.com3 min
NOV 3
$RVTYMed

Revvity, Inc. Q3 2026 Earnings Call Summary

Revvity, Inc. reported Q3 2026 earnings, highlighting a 9% organic growth in Life Sciences, driven by reagent and software demand. Management raised full-year guidance to 5% growth, citing AI-related demand and operational efficiencies. The company expects sustainable margins and plans to divest its China immunodiagnostics business in 2027. Key growth areas include reagents and Signals software, with AI-native offerings launching in 2026.

finance.yahoo.com7 min
NOV 3
$RVTYHighAI 9/10

Revvity Shares Jump Nearly 6% as Q3 Earnings Beat Forecasts and 2026 Guidance Improves

Revvity (RVTY) shares rose 5.55% premarket after Q3 2026 earnings beat estimates, with adjusted EPS of $1.37 vs. $1.30 expected. Revenue grew 4% YoY to $729M, surpassing forecasts. Pro forma revenue, excluding China Immunodiagnostics, increased 7% to $710M. Life Sciences revenue grew 10.8% to $380M, while Diagnostics saw a 2% reported decline but 4% pro forma growth.

finance.yahoo.com5 min
NOV 3
$RVTYHighAI 8/10

Revvity Q3 2026 slides: strong growth, margin expansion lift outlook

Revvity reported Q3 2026 revenue of $710M, up 7% YoY, with adjusted operating margins expanding to 29.4%. EPS grew 21% to $1.37. The company raised full-year guidance, citing strong demand and operational improvements. Life Sciences and Diagnostics segments showed growth, with the Americas and Europe outperforming Asia-Pacific. Revvity's stock surged 8.85% premarket to $165.01.

investing.com2 min